NCT05108051

Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir

A Phase 1, Open-Label, Three-Period, Single-center Study to Assess the Pharmacokinetic Interactions Between ZSP1273 and Oseltamivir in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Guangdong Raynovent Biotech Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

To evaluate the drug-drug interaction between ZSP1273 and oseltamivir, the pharmacokinetic characteristics and safety of ZSP1273 and oseltamivir in healthy subjects, so as to provide a basis for the design of administration regimen in subsequent clinical trials.

Conditions

• Drug-drug Interaction

Interventions

Type	Name	Description
DRUG	ZSP1273	ZSP1273 tablets 600mg administered orally once daily
DRUG	Oseltamivir	Oseltamivir 75mg administered orally twice daily

Timeline

• Start date: 2020-11-19
• Primary completion: 2021-03-17
• Completion: 2021-03-17
• First posted: 2021-11-04
• Last updated: 2021-11-04

Locations

1 site across 1 country: China